|
Reference #:
2001-126
Inventors/Contributors
Elliott Richelson M.D., Mona M. Boules Ph.D.
Description
The invention involves the use of a compound that activates brain receptors for neurotensin as a treatment for Parkinson's Disease. The effects of injections of a neurotensin analog (NT69L) on the rotational behavior inducted by D-amphetaimen (5 mg/kg) or apomorphine (600 ug/kg) were tested in unilaterally 6-hydroxydopamine lesioned rats. Pretreatment of animals with intraperitoneal injections of NT69L (1 mg/kg) resulted in significant reduction of apomorphine-induced contralateral rotation & D-amphetamine-induced ipsilateral rotation in these lesioned rats with an ED50 of 40 ug/kg & 80 ug/kg, respectively. After 3 daily injections, the effects of NT69L on this rotational behavior were unchanged, suggesting that no tolerance develops to this novel compound. See also Mayo Case 1997-126.
Patent Status
Pending |
|
Contact
Nathan L. Stacy, Licensing Manager
stacy.nathan@mayo.edu
|
|
Mayo Foundation for Medical Education and Research
Office of Technology Commercialization
Centerplace 4
200 First Street SW
Rochester, MN 55905
|
Phone: (507) 538-1652
Fax: (507) 284-5410
|
|
|
